The Quadruplet Combination of Carfilzomib, Cyclophosphamide, Lenalidomide, and Dexamethasone is Safe and Well Tolerated as Induction Therapy for Newly Diagnosed, Transplant Eligible, Myeloma Patients

Authors
Publication date
Publisher
Fondazione Ferrata Storti

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Newcastle University E-Prints

    redirect
    oaioai:eprints.ncl.ac.uk:220081
    Last time updated on 30/05/2021